Predictors of Survival Following Y90 DOTATOC/DOTATATE Therapy Abstract #550

Introduction: Y90-DOTATATE and Y90-DOTATOC are established treatments for patients with advanced neuroendocrine tumours. Outcomes associated with improved survival following therapy are still unclear.
Aim(s): To determine clinical, biochemical and radiological response rates to Y90 therapy and their possible association with improved survival.
Materials and methods: A retrospective case note analysis was conducted on 60 patients who had recieved Y90. Clinical response was assessed subjectively. Biochemical and radiological response were assessed using WHO and RECIST criteria, respectively. Survival curves were constructed for responders (stable/regression) v. non-responders (progression).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Timothy Gilbert

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1921 Prognostic Factors That Mandate Long Term Follow Up Following Surgery for Appendiceal Neuroendocrine Tumours (aNETs)
Introduction: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy and rarely recur. Current ENET guidelines inform their management and highlight areas of uncertainty.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Edward Alabraba
Authors: Alabraba E, Banks M, Malik H, Fenwick S, ...
Keywords: Appendix NET
#1814 Predictors of Outcome in Patients Treated with Peptide Radio-Labelled Receptor Target Therapy (PRRT)
Introduction: The efficacy of PRRT has been demonstrated in patients with well differentiated NETS. The NETTER-01 study demonstrated disease stabilisation or partial response in approximately 80% of patients. However, more studies are needed to identify predictors of response
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Georgios Demetriou
Keywords: PRRT, Y90, Lu-177
#307 Prognostic Features in Patients with Metastatic Neuroendocrine Tumor Undergoing Y-90 Embolization
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms originating from enterochromaffin cells. NET patients with liver metastases frequently undergo Yttrium-90 (Y90) embolization.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Michelle Kim
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#1711 Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours
Introduction: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy with 177Lu-octreotate (PRRT) are validated therapies in patients with advanced metastatic neuroendocrine tumours, it is still unclear if the combined therapy with PRRT and SSA can provide a prolonged survival compared to patients treated with PRRT alone.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr. Anna Yordanova